PhoenixBio (6190) · RiskMaterialised
Deferral of a Large-Scale Project Due to a Defective PXB Mouse
First written in FY2022-Q2. 2 of 2 entries say "Materialised", first in FY2022-Q2. Latest entry: FY2022.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Postponement of large projects and retesting costs due to poor PXB mouse conditionA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2022MaterialisedAnnual report
「In terms of expenses, in addition to the increase in net sales, cost of sales increased due to retesting costs for a large project resulting from some of the PXB mice used being defective, as well as higher depreciation expenses for overseas production facilities in which the company had invested.」
Retesting costs for a large project caused by defective PXB mice were identified as a factor behind the full-year increase in cost of sales. - FY2022-Q2MaterialisedAnnual report
「Cost of sales increased because various expenses were incurred in connection with a large project that was postponed after some of the PXB mice used were found to be defective.」
The company stated that a large project was postponed because some of the PXB mice used were defective, resulting in various related expenses and an increase in cost of sales.